ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
14.67
-1.15 (-7.27%)
Aug 14, 2025, 11:44 AM - Market open
ARS Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Cash & Equivalents | 51.54 | 50.82 | 70.97 | 210.52 | 60.06 | 24.52 |
| Short-Term Investments | 188.59 | 263.21 | 157.39 | 63.86 | - | - |
| Cash & Short-Term Investments | 240.13 | 314.02 | 228.36 | 274.38 | 60.06 | 24.52 |
| Cash Growth | 9.78% | 37.51% | -16.77% | 356.82% | 144.94% | - |
| Accounts Receivable | 25.13 | 8.18 | - | - | - | 0.38 |
| Other Receivables | 0.96 | 0.99 | 0.69 | 1.01 | 0 | 0 |
| Receivables | 26.08 | 9.16 | 0.69 | 1.01 | 0 | 0.38 |
| Inventory | 8.74 | 5.21 | - | - | - | - |
| Prepaid Expenses | 4.46 | 4.67 | 2.03 | 2.31 | 0.67 | 1.48 |
| Other Current Assets | 2.03 | 1.23 | 0.65 | - | - | - |
| Total Current Assets | 281.44 | 334.3 | 231.73 | 277.7 | 60.73 | 26.38 |
| Property, Plant & Equipment | 2.64 | 1.07 | 0.82 | 0.77 | 0.69 | 0.02 |
| Other Intangible Assets | 13.16 | 7.69 | 0.62 | - | - | - |
| Other Long-Term Assets | 16.24 | 8.11 | 0.02 | 2.96 | 0.02 | 0 |
| Total Assets | 313.47 | 351.15 | 233.19 | 281.44 | 61.45 | 26.41 |
| Accounts Payable | 16.1 | 14.13 | 0.76 | 1.66 | 1.79 | 1.22 |
| Accrued Expenses | 10.68 | 4.15 | 0.36 | 2.1 | 1.3 | 0.84 |
| Current Portion of Long-Term Debt | - | - | - | - | 3.48 | 2.56 |
| Current Portion of Leases | 0.59 | 0.04 | 0.24 | 0.23 | 0.14 | - |
| Current Income Taxes Payable | - | - | - | 0.17 | - | - |
| Current Unearned Revenue | 0.75 | 0.56 | - | 0.28 | 1.46 | 3.52 |
| Other Current Liabilities | 17.49 | 4.57 | 1.04 | 1 | 0.02 | 0.08 |
| Total Current Liabilities | 45.6 | 23.44 | 2.39 | 5.44 | 8.19 | 8.21 |
| Long-Term Debt | 71.96 | 69.38 | - | - | 4.93 | 7.46 |
| Long-Term Leases | 1.07 | - | 0.04 | 0.25 | 0.48 | - |
| Long-Term Unearned Revenue | 1.1 | 1.53 | - | 2.85 | 3 | 3.44 |
| Other Long-Term Liabilities | 1.42 | - | - | - | 0.08 | 0.11 |
| Total Liabilities | 121.15 | 94.36 | 2.43 | 8.55 | 16.68 | 19.23 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.22 |
| Additional Paid-In Capital | 394.49 | 379.87 | 362 | 349.41 | 10.98 | 7.74 |
| Retained Earnings | -202.13 | -123.31 | -131.3 | -76.94 | -42.26 | -22.01 |
| Comprehensive Income & Other | -0.05 | 0.22 | 0.05 | 0.41 | - | - |
| Total Common Equity | 192.32 | 256.8 | 230.76 | 272.89 | -31.27 | -14.05 |
| Shareholders' Equity | 192.32 | 256.8 | 230.76 | 272.89 | 44.77 | 7.18 |
| Total Liabilities & Equity | 313.47 | 351.15 | 233.19 | 281.44 | 61.45 | 26.41 |
| Total Debt | 73.62 | 69.43 | 0.27 | 0.48 | 9.03 | 10.02 |
| Net Cash (Debt) | 166.51 | 244.6 | 228.09 | 273.9 | 51.03 | 14.5 |
| Net Cash Growth | -23.82% | 7.24% | -16.73% | 436.74% | 251.86% | - |
| Net Cash Per Share | 1.70 | 2.39 | 2.40 | 6.86 | 1.77 | 0.72 |
| Filing Date Shares Outstanding | 98.83 | 98.12 | 96.5 | 94.4 | 25.7 | 20.22 |
| Total Common Shares Outstanding | 98.7 | 97.95 | 96.41 | 93.94 | 25.7 | 20.22 |
| Working Capital | 235.84 | 310.86 | 229.34 | 272.26 | 52.54 | 18.17 |
| Book Value Per Share | 1.95 | 2.62 | 2.39 | 2.90 | -1.22 | -0.70 |
| Tangible Book Value | 179.16 | 249.11 | 230.14 | 272.89 | -31.27 | -14.05 |
| Tangible Book Value Per Share | 1.82 | 2.54 | 2.39 | 2.90 | -1.22 | -0.70 |
| Machinery | - | 1.21 | 0.67 | 0.38 | 0.09 | 0.03 |
| Leasehold Improvements | - | 0.02 | 0.02 | - | - | - |
Updated Aug 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.